Avastin plus PC demonstrated superior survival in first-line advanced nsNSCLC

In Study E4599, median OS with Avastin plus PC was 12.3 months vs 10.3 months with PC alone (HR=0.80 [95% CI, 0.68–0.94], P=0.013).[1]

nsNSCLC=non-squamous non-small cell lung cancer; OS=overall survival; PC=paclitaxel + carboplatin; HR=hazard ratio; CI=confidence interval.

*Insurer/payer policies are subject to change. The completion and submission of coverage or reimbursement-related documentation are the responsibility of the patient and the healthcare provider. Genentech makes no guarantee concerning coverage or reimbursement for any service or item. Inclusion of a plan or product is not intended to imply a recommendation of a particular plan or product. Coverage percentage shown is a weighted average based on national patients treated for Avastin.
As of 01/01/2021, national coverage for Avastin is 85%+.